Tvardi Therapeutics, Inc.

NasdaqCM:TVRD Stock Report

Market Cap: US$19.0m

Tvardi Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of TVRD?
Owner TypeNumber of SharesOwnership Percentage
Public Companies68,4880.73%
Hedge Funds704,1187.51%
VC/PE Firms761,2878.11%
General Public2,136,18222.8%
Individual Insiders2,176,15723.2%
Institutions3,535,11237.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 72.51% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.93%
Sporos Bioventures
837,636US$1.7m0%no data
8.11%
Solas BioVentures
761,287US$1.5m0%no data
7.51%
Slate Path Capital LP
704,118US$1.4m0%0.02%
6.91%
David Tweardy
648,374US$1.3m0%no data
5.71%
Brown Advisory Incorporated
535,250US$1.1m0%no data
4.7%
Imran Alibhai
441,189US$891.2k19%no data
4.54%
Ronald DePinho
426,190US$860.9k0%no data
4.14%
BlackRock, Inc.
388,075US$783.9k-0.75%no data
3.67%
Vanguard Capital Management, LLC
344,708US$696.3k0%no data
3.36%
Samuel Tweardy
315,658US$637.6k0%no data
2.38%
American Money Management Corporation
223,659US$451.8k0%0.07%
1.94%
Geode Capital Management, LLC
182,339US$368.3k16%no data
1.14%
Dan Conn
107,319US$216.8k34.5%no data
1.08%
Silvercrest Asset Management Group LLC
101,034US$204.1k0%no data
1.04%
State Street Global Advisors, Inc.
97,231US$196.4k-15.8%no data
0.98%
Renaissance Technologies LLC
92,100US$186.0k-11.9%no data
0.94%
Palkon Capital Management LLC
87,721US$177.2k0%no data
0.83%
John Kauh
77,527US$156.6k67.5%no data
0.77%
Morgan Stanley
72,486US$146.4k-12.9%no data
0.73%
CSL Limited
68,488US$138.3k0%no data
0.72%
BioMatrix Partners, Ltd.
67,348US$136.0k0%100.0%
0.67%
Duncan Williams Asset Management, LLC
63,241US$127.7k-21.7%0.03%
0.64%
Shaheen Wirk
60,074US$121.4k0%no data
0.54%
UBS Asset Management AG
50,454US$101.9k41.9%no data
0.52%
Northern Trust Global Investments
49,081US$99.1k2.5%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/04 21:05
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tvardi Therapeutics, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBarclays
Julian HarrisonBTIG
Steven SeedhouseCantor Fitzgerald & Co.